SEC Form 4
Veracyte, Inc. (VCYT) insider trading
In the 12 months to Oct 26, 2026, 11 VCYT insiders reported open-market sales of $21.1M across 34 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $21.1M
- 34 filings · 11 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 32 of 34
- $19.6M of $21.1M sold (93%)
Who traded VCYT, and when
- Sale
- Sale, pre-arranged (10b5-1)
VCYT daily close from Oct 27, 2025 to Oct 26, 2026, between $30.01 and $60.49, last $47.82. 34 sale and 0 purchase filings by 11 insiders, marked at their filing dates. Marc Stapley, Chief Executive Officer: sold $8.9M across 3 filings, first filed Dec 4, 2025, last Jun 4, 2026. Evan/ Fa Jones, Director: sold $2.0M across 2 filings, first filed Nov 7, 2025, last Nov 26, 2025. Rebecca Chambers, Chief Financial Officer: sold $1.9M across 5 filings, first filed Nov 7, 2025, last Sep 4, 2026. Annie McGuire, SVP, General Counsel → EVP, General Counsel: sold $1.7M across 7 filings, first filed Nov 7, 2025, last Sep 4, 2026. Jonathan Wygant, VP, Chief Accounting Officer: sold $1.5M across 2 filings, first filed Nov 12, 2025, last May 27, 2026. Karin Eastham, Director: sold $1.5M across 3 filings, first filed Nov 7, 2025, last Jun 22, 2026. 5 others: sold $3.5M across 12 filings, first filed Nov 21, 2025, last Oct 20, 2026.
Largest mark · tap a row for others
Marc Stapley · Chief Executive Officer
Sale $6,919,585
138,051 shares at $50.12 avg
Filed Jun 4, 2026
Pre-arranged (10b5-1) · close on filing date $49.94
Marc Stapley · Chief Executive Officer
Chief Executive Officer
$8.9M soldEvan/ Fa Jones · Director
Director
$2.0M soldRebecca Chambers · Chief Financial Officer
Chief Financial Officer
$1.9M soldAnnie McGuire · SVP, General Counsel → EVP, General Counsel
SVP, General Counsel → EVP, General Counsel
$1.7M soldJonathan Wygant · VP, Chief Accounting Officer
VP, Chief Accounting Officer
$1.5M soldKarin Eastham · Director
Director
$1.5M sold5 others
Combined, one mark per week
$3.5M soldOpen-market trades
34 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Marc Stapley | Chief Executive Officer | $8.9M | — | 3 | 100% of sales | |
| Evan/ Fa Jones | Director | $2.0M | — | 2 | 100% of sales | |
| Rebecca Chambers | Chief Financial Officer | $1.9M | — | 5 | 100% of sales | |
| Annie McGuire | SVP, General Counsel → EVP, General Counsel | $1.7M | — | 7 | 100% of sales | |
| Jonathan Wygant | VP, Chief Accounting Officer | $1.5M | — | 2 | — | |
| Karin Eastham | Director | $1.5M | — | 3 | 100% of sales | |
| John Leite | Chief Commercial Officer-CLIA → Global Chief Commercial Off | $1.2M | — | 5 | 100% of sales | |
| Phillip G. Febbo | Chief Scientific & Med Officer | $1.0M | — | 2 | 100% of sales | |
| Jens Holstein | Director | $628.3K | — | 2 | 100% of sales | |
| Robert S. Epstein | Director | $440.1K | — | 1 | 100% of sales | |
| Muna Bhanji | Director | $161.6K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Muna Bhanji Director | SalePre-arranged (10b5-1) | 1,864 | $43.70 | $81.5K | 40,854 | |
traded | John Leite Global Chief Commercial Off | SalePre-arranged (10b5-1) | 4,015 | $40.00 | $160.6K | 124,329 | |
traded | Jens Holstein Director | SalePre-arranged (10b5-1) | 5,000 | $40.95 | $204.7K | 27,471 | |
traded | Phillip G. Febbo Chief Scientific & Med Officer | SalePre-arranged (10b5-1) | 13,110 | $43.05 | $564.4K | 133,048 | |
traded | Rebecca Chambers Chief Financial Officer | SalePre-arranged (10b5-1) | 3,652 | $43.10 | $157.4K | 167,200 | |
traded | Annie McGuire EVP, General Counsel | SalePre-arranged (10b5-1) | 3,254 | $43.09 | $140.2K | 131,160 | |
traded | Muna Bhanji Director | SalePre-arranged (10b5-1) | 1,864 | $42.97 | $80.1K | 42,718 | |
traded | Karin Eastham Director | SalePre-arranged (10b5-1) | 3,729 | $52.89 | $197.2K | 15,626 | |
traded | Marc Stapley Chief Executive Officer | SalePre-arranged (10b5-1) | 138,051 | $50.12 | $6.9M | 440,494 | |
traded | Rebecca Chambers Chief Financial Officer | SalePre-arranged (10b5-1) | 3,561 | $49.73 | $177.1K | 175,241 | |
traded | Annie McGuire EVP, General Counsel | SalePre-arranged (10b5-1) | 3,176 | $49.76 | $158.0K | 137,240 | |
traded | John Leite Global Chief Commercial Off | SalePre-arranged (10b5-1) | 13,975 | $50.07 | $699.7K | 132,305 | |
traded | Jonathan Wygant VP, Chief Accounting Officer | Sale | 24,000 | $45.40 | $1.1M | 45,434 | |
traded | Robert S. Epstein Director | SalePre-arranged (10b5-1) | 10,000 | $44.01 | $440.1K | 52,446 | |
traded | Annie McGuire SVP, General Counsel | SalePre-arranged (10b5-1) | 10,204 | $39.03 | $398.2K | 148,810 | |
traded | Marc Stapley Chief Executive Officer | SalePre-arranged (10b5-1) | 45,523 | $35.97 | $1.6M | 357,554 | |
traded | Rebecca Chambers Chief Financial Officer | SalePre-arranged (10b5-1) | 18,341 | $36.14 | $662.9K | 131,196 | |
traded | Annie McGuire SVP, General Counsel | SalePre-arranged (10b5-1) | 6,658 | $35.55 | $236.7K | 94,706 | |
traded | John Leite Chief Commercial Officer-CLIA | SalePre-arranged (10b5-1) | 5,260 | $35.19 | $185.1K | 107,580 | |
traded | Phillip G. Febbo Chief Scientific & Med Officer | SalePre-arranged (10b5-1) | 13,425 | $36.16 | $485.4K | 117,346 | |
traded | Annie McGuire SVP, General Counsel | SalePre-arranged (10b5-1) | 10,739 | $43.13 | $463.2K | 67,760 | |
traded | Karin Eastham Director | SalePre-arranged (10b5-1) | 20,000 | $45.45 | $908.9K | 13,554 | |
traded | Marc Stapley Chief Executive Officer | SalePre-arranged (10b5-1) | 7,668 | $47.09 | $361.1K | 321,823 | |
traded | Rebecca Chambers Chief Financial Officer | SalePre-arranged (10b5-1) | 13,278 | $46.84 | $622.0K | 109,496 | |
traded | Annie McGuire SVP, General Counsel | SalePre-arranged (10b5-1) | 1,422 | $47.30 | $67.3K | 78,499 | |
traded | John Leite Chief Commercial Officer-CLIA | SalePre-arranged (10b5-1) | 1,278 | $47.51 | $60.7K | 82,113 | |
traded | Evan/ Fa Jones Director | SalePre-arranged (10b5-1) | 1,106 | $50.25 | $55.6K | 29,362 | |
traded | John Leite Chief Commercial Officer-CLIA | SalePre-arranged (10b5-1) | 2,808 | $50.00 | $140.4K | 86,291 | |
traded | Jens Holstein Director | SalePre-arranged (10b5-1) | 10,000 | $42.36 | $423.6K | 35,708 | |
traded | Jonathan Wygant VP, Chief Accounting Officer | Sale | 10,920 | $41.20 | $449.9K | 38,745 | |
traded | Evan/ Fa Jones Director | SalePre-arranged (10b5-1) | 43,196 | $45.06 | $1.9M | 72,130 | |
traded | Karin Eastham Director | SalePre-arranged (10b5-1) | 9,674 | $40.02 | $387.2K | 13,554 | |
traded | Rebecca Chambers Chief Financial Officer | SalePre-arranged (10b5-1) | 7,000 | $41.00 | $287.0K | 126,158 | |
traded | Annie McGuire SVP, General Counsel | SalePre-arranged (10b5-1) | 6,466 | $40.00 | $258.6K | 82,973 |
GET /stocks/filings/vX/form-4?tickers=VCYT&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"VCYT"
],
"issuer_cik": "0001384101",
"owner_cik": "0001846905",
"accession_number": "0001846905-26-000008",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-19",
"issuer_name": "VERACYTE, INC.",
"issuer_trading_symbol": "VCYT",
"owner_name": "Bhanji Muna",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-19",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1864,
"transaction_price_per_share": 43.7,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 40854,
"transaction_value": 81456.8,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026."
}
]
},
{
"tickers": [
"VCYT"
],
"issuer_cik": "0001384101",
"owner_cik": "0001991536",
"accession_number": "0001991536-26-000013",
"form_type": "4",
"filing_date": "2026-09-22",
"period_of_report": "2026-09-21",
"issuer_name": "VERACYTE, INC.",
"issuer_trading_symbol": "VCYT",
"owner_name": "Leite John",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Global Chief Commercial Off",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4015,
"transaction_price_per_share": 40,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 124329,
"transaction_value": 160600,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 61 records
- Option exercises7 records
- Tax withholding29 records
- Grants and awards25 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Veracyte, Inc.'s CEO sold stock?
Yes. Marc Stapley (CEO) sold 191,242 shares ($8.9M) between Dec 2025 and Jun 2026, all under a pre-arranged 10b5-1 plan.
How current is VCYT’s insider data?
These are VCYT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track VCYT insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for VCYT every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.